Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents.
Adenosine receptor
adenosine a3 receptor
anti-inflammatory
bioactive heterocycles
immune disorders
neuroprotective.
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
05
2019
accepted:
03
07
2019
pubmed:
25
7
2019
medline:
21
4
2020
entrez:
24
7
2019
Statut:
ppublish
Résumé
Adenosine receptors (ARs) belongs to the family of G-protein coupled receptors (GPCR) that are responsible for the modulation of a wide variety of physiological functions. The ARs are also implicated in many diseases such as cancer, arthritis, cardiovascular and renal diseases. The adenosine A3 receptor (A3AR) has emerged as a potential drug target for the progress of new and effective therapeutic agents for the treatment of various pathological conditions. This receptor's involvement in many diseases and its validity as a target has been established by many studies. Both agonists and antagonists of A3AR have been extensively investigated in the last decade with the goal of developing novel drugs for treating diseases related to immune disorders, inflammation, cancer, and others. In this review, we shall focus on the medicinal chemistry of A3AR ligands, exploring the diverse chemical classes that have been projected as future leading drug candidates. Also, the recent advances in the therapeuetic applications of A3AR ligands are highlighted.
Identifiants
pubmed: 31333098
pii: CPD-EPUB-99666
doi: 10.2174/1381612825666190716114056
doi:
Substances chimiques
Adenosine A3 Receptor Agonists
0
Adenosine A3 Receptor Antagonists
0
Ligands
0
Receptor, Adenosine A3
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2772-2787Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.